HeartSciences EBITDA 2022-2025 | HSCS
HeartSciences ebitda from 2022 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
| HeartSciences Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $-8 |
| 2024 | $-6 |
| 2023 | $-6 |
| 2022 | $-5 |
| 2021 | $-3 |
| HeartSciences Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-04-30 | $-2 |
| 2025-01-31 | $-2 |
| 2024-10-31 | $-2 |
| 2024-07-31 | $-2 |
| 2024-04-30 | $-2 |
| 2024-01-31 | $-1 |
| 2023-10-31 | $-1 |
| 2023-07-31 | $-1 |
| 2023-04-30 | $-1 |
| 2023-01-31 | $-1 |
| 2022-10-31 | $-2 |
| 2022-07-31 | $-1 |
| 2022-04-30 | $-2 |
| 2022-01-31 | $-1 |
| 2021-10-31 | $-1 |
| 2021-07-31 | $-1 |
| 2021-04-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.009B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $46.412B | 59.05 |
| Tempus AI (TEM) | United States | $12.731B | 0.00 |
| Doximity (DOCS) | United States | $12.055B | 53.63 |
| Hims & Hers Health (HIMS) | United States | $9.805B | 80.33 |
| IRhythm Technologies (IRTC) | United States | $5.243B | 0.00 |
| Hinge Health (HNGE) | United States | $4.466B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.752B | 40.46 |
| Privia Health (PRVA) | United States | $2.596B | 192.27 |
| Heartflow (HTFL) | $2.379B | 0.00 | |
| Enovis (ENOV) | United States | $1.715B | 9.06 |
| 10x Genomics (TXG) | United States | $1.663B | 0.00 |
| Phreesia (PHR) | United States | $1.648B | 0.00 |
| Omnicell (OMCL) | United States | $1.458B | 28.10 |
| Schrodinger (SDGR) | United States | $1.425B | 0.00 |
| Azenta (AZTA) | United States | $1.365B | 59.54 |
| Clover Health Investments (CLOV) | United States | $1.302B | 0.00 |
| Claritev (CTEV) | United States | $1.088B | 0.00 |
| Evolent Health (EVH) | United States | $1.052B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.654B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.568B | 0.00 |
| Veradigm (MDRX) | United States | $0.531B | 0.00 |
| Standard BioTools (LAB) | United States | $0.470B | 0.00 |
| Talkspace (TALK) | United States | $0.430B | 128.50 |
| Butterfly Network (BFLY) | United States | $0.355B | 0.00 |
| Carlsmed (CARL) | United States | $0.320B | 0.00 |
| TruBridge (TBRG) | United States | $0.291B | 51.03 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.242B | 0.00 |
| Outset Medical (OM) | United States | $0.237B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.216B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.205B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.192B | 0.00 |
| CapsoVision (CV) | United States | $0.184B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.139B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.133B | 0.00 |
| CareCloud (CCLD) | United States | $0.112B | 5.08 |
| American Well (AMWL) | United States | $0.111B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.077B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.072B | 0.00 |
| 111 (YI) | China | $0.063B | 0.00 |
| Pulmonx (LUNG) | United States | $0.062B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.053B | 0.00 |
| HeartBeam (BEAT) | United States | $0.039B | 0.00 |
| Precipio (PRPO) | United States | $0.024B | 0.00 |
| Zhongchao (ZCMD) | China | $0.022B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.012B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.007B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| PROFUSA (PFSA) | United States | $0.003B | 0.00 |